Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 2Completed 2Withdrawn 1Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Ovarian Neoplasms 368Uterine Cervical Neoplasms 144Carcinoma, Ovarian Epithelial 108Fallopian Tube Neoplasms 105Endometrial Neoplasms 99Breast Neoplasms 82Carcinoma, Non-Small-Cell Lung 70Neoplasms 55Stomach Neoplasms 49Melanoma 44Colorectal Neoplasms 44Neoplasm Metastasis 40Pancreatic Neoplasms 37Carcinoma, Renal Cell 36Triple Negative Breast Neoplasms 33Recurrence 31Squamous Cell Carcinoma of Head and Neck 28Lung Neoplasms 28Uterine Neoplasms 25Sarcoma 25Urinary Bladder Neoplasms 24Peritoneal Neoplasms 24Uterine Cervical Dysplasia 23Prostatic Neoplasms 23Colonic Neoplasms 23Esophageal Neoplasms 22Head and Neck Neoplasms 21Carcinoma, Transitional Cell 18Testicular Neoplasms 16Small Cell Lung Carcinoma 16

Interventions

Paclitaxel 1Gemcitabine 1Doxorubicin 1Docetaxel 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Advanced Endometrial Cancer × Gynecologic × Clear all
NCT05481645 2026-01-09

Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus.

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2 Terminated
71 enrolled
GynecologicSarcoma

Advanced Endometrial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡